JP2023113751A5 - - Google Patents

Download PDF

Info

Publication number
JP2023113751A5
JP2023113751A5 JP2023088154A JP2023088154A JP2023113751A5 JP 2023113751 A5 JP2023113751 A5 JP 2023113751A5 JP 2023088154 A JP2023088154 A JP 2023088154A JP 2023088154 A JP2023088154 A JP 2023088154A JP 2023113751 A5 JP2023113751 A5 JP 2023113751A5
Authority
JP
Japan
Prior art keywords
formulation
salt
amino acids
chloride
anions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023088154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023113751A (ja
Filing date
Publication date
Priority claimed from JP2021167771A external-priority patent/JP7338890B2/ja
Application filed filed Critical
Publication of JP2023113751A publication Critical patent/JP2023113751A/ja
Publication of JP2023113751A5 publication Critical patent/JP2023113751A5/ja
Pending legal-status Critical Current

Links

JP2023088154A 2014-05-28 2023-05-29 Tat-NR2B9cの塩化物塩 Pending JP2023113751A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004142P 2014-05-28 2014-05-28
US62/004,142 2014-05-28
JP2021167771A JP7338890B2 (ja) 2014-05-28 2021-10-13 Tat-NR2B9cの塩化物塩

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021167771A Division JP7338890B2 (ja) 2014-05-28 2021-10-13 Tat-NR2B9cの塩化物塩

Publications (2)

Publication Number Publication Date
JP2023113751A JP2023113751A (ja) 2023-08-16
JP2023113751A5 true JP2023113751A5 (https=) 2023-11-30

Family

ID=54698210

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016569655A Expired - Fee Related JP6622222B2 (ja) 2014-05-28 2015-05-28 Tat−NR2B9cの塩化物塩
JP2019210223A Expired - Fee Related JP6961661B2 (ja) 2014-05-28 2019-11-21 Tat−NR2B9cの塩化物塩
JP2021167771A Active JP7338890B2 (ja) 2014-05-28 2021-10-13 Tat-NR2B9cの塩化物塩
JP2023088154A Pending JP2023113751A (ja) 2014-05-28 2023-05-29 Tat-NR2B9cの塩化物塩

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2016569655A Expired - Fee Related JP6622222B2 (ja) 2014-05-28 2015-05-28 Tat−NR2B9cの塩化物塩
JP2019210223A Expired - Fee Related JP6961661B2 (ja) 2014-05-28 2019-11-21 Tat−NR2B9cの塩化物塩
JP2021167771A Active JP7338890B2 (ja) 2014-05-28 2021-10-13 Tat-NR2B9cの塩化物塩

Country Status (27)

Country Link
US (4) US10206973B2 (https=)
EP (2) EP3149048B1 (https=)
JP (4) JP6622222B2 (https=)
KR (3) KR102605540B1 (https=)
CN (2) CN106661126B (https=)
AU (2) AU2015265487B2 (https=)
BR (1) BR112016027814A2 (https=)
CA (1) CA2950395C (https=)
CY (1) CY1122793T1 (https=)
DK (1) DK3149048T3 (https=)
ES (2) ES2974228T3 (https=)
HR (1) HRP20200462T1 (https=)
HU (1) HUE049074T2 (https=)
IL (1) IL249252B (https=)
LT (1) LT3149048T (https=)
ME (1) ME03790B (https=)
MX (2) MX374958B (https=)
PL (1) PL3149048T3 (https=)
PT (1) PT3149048T (https=)
RS (1) RS60625B1 (https=)
RU (2) RU2707885C2 (https=)
SG (2) SG11201609911YA (https=)
SI (1) SI3149048T1 (https=)
SM (1) SMT202000307T1 (https=)
UA (1) UA123820C2 (https=)
WO (1) WO2015181756A1 (https=)
ZA (1) ZA201608843B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
US10251935B2 (en) * 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2015181757A1 (en) 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
CN106661126B (zh) 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
MA54884A (fr) 2015-07-01 2022-01-12 Immatics Biotechnologies Gmbh Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen ovarialkarzinom und andere karzinome
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201620611D0 (en) * 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
BR112020000115A2 (pt) * 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
JP2023511057A (ja) * 2020-01-09 2023-03-16 ノノ インコーポレイテッド 脳卒中及び関連疾患を治療するためのプラスミン耐性ペプチド
CN111560050A (zh) * 2020-05-25 2020-08-21 成都圣诺生物制药有限公司 一种Nerinetide的制备方法
CA3203688A1 (en) 2021-01-08 2022-07-14 Jonathan David Garman Plasmin-resistant peptides for improved therapeutic index
CN113735938B (zh) * 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
EP4706670A1 (en) 2023-04-26 2026-03-11 Shenzhen Salubris Pharmaceuticals Co., Ltd. Psd-95 domain inhibitor, and preparation method therefor and use thereof
WO2026012336A1 (zh) * 2024-07-08 2026-01-15 福建盛迪医药有限公司 一种psd-95多肽抑制剂的可药用盐及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2434840T3 (es) * 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US9101590B2 (en) * 2005-07-29 2015-08-11 Yale University Defined culture conditions of human embryonic stem cells
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
DK2120987T3 (en) 2007-03-02 2014-02-24 Nono Inc Treatment of stroke and other diseases without inhibiting N-type calcium channels
US7879805B2 (en) * 2007-06-01 2011-02-01 Acologix, Inc. High temperature stable peptide formulation
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
WO2010004003A2 (en) * 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction
PT2440230T (pt) 2009-06-10 2021-02-03 Nono Inc Regimes de tratamento para tratamento de doenças neurológicas
ES2655112T3 (es) * 2010-08-12 2018-02-16 Nono Inc. Tratamiento de una lesión penetrante en el cerebro
RU2607033C2 (ru) * 2010-09-28 2017-01-10 Ноно Инк. Пептиды nd2 и способы лечения неврологического заболевания
ES2544573T3 (es) * 2011-05-13 2015-09-01 Københavns Universitet (University Of Copenhagen) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
CN102241745A (zh) * 2011-05-19 2011-11-16 南京医科大学 多肽类似物Tat-HA-NR2B9C及其制备方法和应用
EP2723363B1 (en) * 2011-06-24 2018-08-29 NoNO Inc. Combination therapy for ischemia
US9241970B2 (en) * 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
JP6279483B2 (ja) 2011-12-13 2018-02-14 ノノ インコーポレイテッド くも膜下出血および虚血の治療法
GB201220474D0 (en) * 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
PL2925338T3 (pl) 2012-11-28 2019-11-29 Nono Inc Liofilizowana formulacja TAT-NR2B9C
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
CN106661126B (zh) 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
WO2015181757A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger

Similar Documents

Publication Publication Date Title
JP2023113751A5 (https=)
US8785375B2 (en) Cyclic antimicrobial peptides for treating bacterial infections
JP3533216B2 (ja) 乳頭腫ウイルスl2蛋白
US9518093B2 (en) Topical formulation of arginine-rich cyclic antimicrobial peptides
JP2024503265A5 (https=)
JP2021521159A5 (https=)
JP2022088521A5 (https=)
EP1985625B1 (en) Synthetic peptide constructs for the diagnosis and treatment of periodontitis associated with Porphyromonas gingivalis
JP2023529839A5 (https=)
JP2021526505A5 (https=)
JP2020015742A5 (https=)
WO2016046523A1 (en) Use of cystamine for treating bacterial and fungal infections
JP5403867B2 (ja) 急速分散性医薬固形剤形における食用酸の使用
CN116406286A (zh) 免疫调节化合物及其用于治疗和/或预防传染性疾病的用途
KR20230002361A (ko) 카파 오피오이드 수용체 효능제의 올리고당 제형
JP2001524083A (ja) テイコプラニン誘導体
JP2020528426A (ja) 感染症治療用ラクトフェリシン及びラクトフェランピン
AU764061B2 (en) Use of active P40 conjugates for nasal delivery
JP2021521168A5 (https=)
CN101389642B (zh) 环状抗微生物肽
JP2025511086A5 (https=)
JP2024512722A5 (https=)
CA2204618A1 (fr) Proteine g du virus respiratoire syncytial exprimee sur membrane bacterienne
JP2023525565A5 (https=)
JPH1180021A (ja) バンコマイシン注射剤